Abstracts tagged "Disease Activity"

Abstract Number: 1829 • 2019 ACR/ARP Annual Meeting
Ability of Inflammatory and Regulatory Soluble Mediators to Forecast Impending Clinical Disease Flare and Inform a Refined Lupus Flare Prediction Index in a Confirmatory Cohort of SLE Patients
Melissa E. Munroe¹, Sarah Kleckner ¹, Wade DeJager ¹, Susan R. Macwana ¹, Joel Guthridge ², Eldon Jupe ³, Mohan Purushothaman ³, Sanjiv Sharma ³, Nancy Redinger ¹, Teresa Aberle ¹, Stan Kamp ¹, Cristina Arriens ², Eliza F. Chakravarty ², Joan T. Merrill ⁴ and Judith James ², ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Progentec Diagnostics, Inc., Oklahoma City, OK, ⁴Okalahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: SLE is marked by altered immune regulation linked to waxing and waning clinical disease activity. This study seeks to verify the alteration of inflammatory…
Abstract Number: 946 • 2019 ACR/ARP Annual Meeting
Improvements in Disease Activity and Quality of Life for up to 64 Weeks in Patients with Behçet’s Syndrome: Results from a Phase III Study
Gulen Hatemi¹, Alfred Mahr ², Mitsuhiro Takeno ³, Doyoung Kim ⁴, Melike Melikoglu ⁵, Sue Cheng ⁶, Shannon McCue ⁷, Maria Paris ⁶, Mindy Chen ⁸ and Yusuf Yazici ⁹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University-Cerrahpasa, Behcet's Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, ²Hospital Saint-Louis, University Paris Diderot, Paris, France, ³Nippon Medical School, Tokyo, Japan, ⁴Yonsei University College of Medicine and Severance Hospital, Seoul, Republic of Korea, ⁵Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul University – Cerrahpasa, Behçet’s Disease Research Center, Istanbul, Turkey, Istanbul, Turkey, ⁶Celgene Corporation, Summit, ⁷Celgene Corporation, Summit, NJ, ⁸Celgene Corporation, Berkeley Heights, NJ, ⁹New York University School of Medicine, New York
Background/Purpose: Behçet’s syndrome is a chronic, multi-system inflammatory disorder characterized by painful, recurrent oral ulcers (OU) that can impair quality of life (QoL). Apremilast (APR),…
Abstract Number: 1865 • 2019 ACR/ARP Annual Meeting
Improving Lupus Care Index Documentation in Patients with Childhood-Onset Systemic Lupus Erythematosus (cSLE)
Fatima Barbar-Smiley¹, Stephanie Lemle ¹, Cagri Yildirim-Toruner ¹, Edward Oberle ¹, Darby McDonald ¹, Vidya Sivaraman ² and Stacy Ardoin ¹, ¹Nationwide Children's Hospital, Columbus, OH, ²Nationwide Children's Hospital and The Ohio State University, Columbus, OH
Background/Purpose: Systemic lupus erythematosus (SLE) affects both adults and children with an estimated prevalence in children of 8/100,000. More than 1000 deaths related to SLE…
Abstract Number: 1085 • 2019 ACR/ARP Annual Meeting
Probiotic Use and Psoriatic Arthritis Disease Activity
Madison Grinnell¹, Kristin Wipfler ², Alexis Ogdie ³ and Kaleb Michaud ⁴, ¹University of Nebraska College of Medicine, OMAHA, NE, ²FORWARD, The National Databank for Rheumatic Diseases, Wichita, KS, ³Department of Medicine and Rheumatology and Department of Epidemiology and Biostatistics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, ⁴University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Probiotics have been hypothesized to mediate inflammation through gut microbiome modulation, and growing evidence has suggested that our intestinal gut microbiome may play a…
Abstract Number: 1881 • 2019 ACR/ARP Annual Meeting
Association of Pain Centralization with DMARD Response in Active RA
Andrew Heisler¹, Jing Song ², Dorothy Dunlop ¹, Alyssa Wohlfahrt ³, Marcy Bolster ⁴, Wendy Marder ⁵, Clifton Bingham ⁶, Daniel Clauw ⁷, Tuhina Neogi ⁸ and Yvonne Lee ⁹, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²Northwestern University Feinberg School of Medicine, Worthington, OH, ³Brigham and Woman's Hospital, Boston, MA, ⁴Massachusetts General Hospital, Boston, MA, ⁵Division of Rheumatology, Department of Internal Medicine, Michigan Medicine, Ann Arbor, ⁶Johns Hopkins University, Baltimore, MD, ⁷Division of Rheumatology, Department of Internal Medicine and Division of Anesthesia, Michigan Medicine, Ann Arbor, MI, ⁸Boston University School of Medicine, Boston, MA, ⁹Northwestern University Feinberg School of Medicine, Chicago
Background/Purpose: Despite the availability of potent disease modifying anti-rheumatic drugs (DMARDs), a significant percentage of rheumatoid arthritis (RA) patients do not achieve low disease activity…
Abstract Number: 1156 • 2019 ACR/ARP Annual Meeting
Differences in Clinical Outcomes According to the Healthcare Regime in Colombian Patients with Rheumatoid Arthritis
Julian Barahona-Correa¹, Jorge Florez ¹, Mateo Rodriguez ², Karen Ramirez ³, Paul Mendez-Patarroyo ¹, Paola Coral-Alvarado ¹ and Gerardo Quintana-López ¹, ¹Reumavance Group, section of Rheumatology, Fundacion Santa Fe de Bogota University Hospital, Bogota DC, Distrito Capital de Bogota, Colombia, ²School of Medicine, Universidad de Los Andes, Bogota, Distrito Capital de Bogota, Colombia, ³School of Medicine, Universidad Nacional de Colombia, Bogota DC, Distrito Capital de Bogota, Colombia
Background/Purpose: Rheumatoid Arthritis (RA) generates high impact on patients and healthcare systems. Adequate control of disease activity depends to a large extent on the access…
Abstract Number: 2325 • 2019 ACR/ARP Annual Meeting
High Intensity Interval Training Improves Rheumatoid Arthritis Cardiorespiratory Fitness and Systemic Inflammation in Association with Alterations in Skeletal Muscle Metabolomic Profiles
Brian Andonian¹, David Bartlett ¹, Deborah Muoio ¹, Timothy Koves ¹, Olga Ilkayeva ¹, Andrew Hoselton ¹, Megan Reaves ¹, William Kraus ¹ and Kim Huffman ¹, ¹Duke University, Durham, NC
Background/Purpose: Patients with rheumatoid arthritis (RA) are at greater risk for cardiometabolic disease and early death. It is unclear if current anti-inflammatory pharmacotherapies alone are…
Abstract Number: 1193 • 2019 ACR/ARP Annual Meeting
EMR-integrated Disease Activity Calculators Improve Treatment to Target in Rheumatoid Arthritis
Gabrielle Barbera¹, Jasleen Kahlon ², Manank Patel ³, Scott Pompa ⁴ and Arundathi Jayatilleke ¹, ¹Drexel, Philadelphia, PA, ²Hahnemann, Philadelphia, PA, ³Rutgers, New Brunswick, NJ, ⁴Dartmouth, Lebanon, NH
Background/Purpose: Undertreatment of RA can lead to cumulative joint damage as well as negatively impact emotional health. Recent evidence favors a treat-to-target strategy to achieve…
Abstract Number: 2443 • 2019 ACR/ARP Annual Meeting
A Gender-based Analysis of Disease Activity and Its Relationship with Anxiety, Depression, Fatigue, and Fibromyalgia in Psoriatic Arthritis
Mehmet Tuncay Duruoz¹, Halise Hande Gezer ², Kemal Nas ³, Erkan Kilic ⁴, Betul Sargin ⁵, Sevtap Acer Kasman ¹, Hakan Alkan ⁶, Nilay Sahin ⁷, Gizem Cengiz ⁸, Nihan Cuzdan ⁹, Ilknur Albayrak Gezer ¹⁰, Dilek Keskin ¹¹, Cevriye Mulkoglu ¹², Hatice Resorlu ¹³, Şebnem Ataman ¹⁴, Ajda Bal ¹⁵, Okan Kucukakkas ¹⁶, Ozan Volkan Yurdakul ¹⁶, Meltem Alkan Melikoglu ¹⁷, Yildiray Aydin ³, Fikriye Figen Ayhan ¹⁸, Hatice Bodur ¹⁹, Mustafa Calis ⁸, Erhan Capkin ²⁰, Gul Devrimsel ²¹, Kevser Gök ²², Sami Hizmetli ²³, Ayhan Kamanli ³, Yasar Keskin ¹⁶, Hilal Kocabas ²⁴, Oznur Kutluk ²⁵, Nesrin Sen ²⁶, Omer Faruk Sendur ²⁷, Ibrahim Tekeoglu ³, Sena Tolu ²⁸, Murat Toprak ²⁹ and Tiraje Tuncer ²⁵, ¹Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Turkey, ²Marmara University School of Medicine, PMR Department, Rheumatology Division, İstanbul, Istanbul, Turkey, ³Sakarya University School of Medicine, PMR Department, Rheumatology and Immunology Division, Sakarya, Turkey, ⁴Afyonkarahisar State Hospital, Afyonkarahisar, Turkey, ⁵Adnan Menderes University School of Medicine, PMR Department, Rheumatology Division, Aydın, Turkey, ⁶Pamukkale University School of Medicine, PMR Department, Rheumatology Division, Denizli, Turkey, ⁷Balıkesir University School of Medicine, PMR Department, Balıkesir, Turkey, ⁸Erciyes University School of Medicine, PMR Department, Rheumatology Division, Kayseri, Turkey, ⁹Şanlıurfa Training and Research Hospital, Rheumatology Clinic, Şanlıurfa, Turkey, ¹⁰Selçuk University School of Medicine, PMR Department, Konya, Turkey, ¹¹Kırıkkale University School of Medicine, PMR Department, Kırıkkale, Turkey, ¹²Ankara Training and Research Hospital, PMR Clinic, Ankara, Turkey, ¹³Çanakkale Onsekiz Mart University School of Medicine, PMR Department, Çanakkale, Turkey, ¹⁴Ankara University School of Medicine, Physical Medicine and Rehabilitation, Rheumatology Department, Ankara, Ankara, Turkey, ¹⁵Dışkapı Yıldırım Beyazıt Training and Research Hospital, PMR Clinic, Ankara, Turkey, ¹⁶Bezmialem Vakıf University School of Medicine, PMR Department, İstanbul, Turkey, ¹⁷Atatürk University School of Medicine, PMR Department, Rheumatology Division, Erzurum, Turkey, ¹⁸Uşak University School of Health Sciences, PMR Department, Uşak, Turkey, ¹⁹Yıldırım Beyazıt University School of Medicine, PMR Department, Ankara, Turkey, ²⁰Karadeniz Teknik University School of Medicine, PMR Department, Trabzon, Turkey, ²¹Recep Tayyip Erdoğan University School of Medicine, PMR Department, Riza, Turkey, ²²Numune Training and Research Hospital, Rheumatology Clinic, Ankara, Turkey, ²³Cumhuriyet University School of Medicine, PMR Department, Rheumatology Division, Sivas, Turkey, ²⁴Necmettin Erbakan University Meram School of Medicine, PMR Department, Rheumatology Division, Konya, Turkey, ²⁵Akdeniz University School of Medicine, PMR Department, Rheumatology Division, Antalya, Turkey, ²⁶Kartal Dr. Lütfi Kırdar Training and Research Hospital, Rheumatology Clinic, İstanbul, Turkey, ²⁷Adnan Menderes University School of Medicine, PMR Department, Aydın, Turkey, ²⁸Medipol University School of Medicine, PMR Department, İstanbul, Turkey, ²⁹Yüzüncü Yıl University School of Medicine, PMR Department, Van, Turkey
Background/Purpose: This study sought to compare the disease activity and its relationship with anxiety, depression, fatigue, and fibromyalgia of patients with psoriatic arthritis (PsA) between…
Abstract Number: 36 • 2019 ACR/ARP Annual Meeting
Discovery, Verification and Validation of Rheumatoid Arthritis Activity Monitoring Biomarkers
Lucía González-Rodríguez¹, Valentina Calamia ¹, Rocío Paz-González ¹, Patricia Fernández-Puente ¹, Cristina Ruiz-Romero ¹, Antonio Julià ², Antonio Fernández-Nebro ³, Jesús Tornero ⁴, Sara Marsal ⁵ and Francisco J. Blanco ⁶, ¹Proteomics Group, Rheumatology Division, ProteoRed, PRB2-ISCIII. INIBIC-Hospital Universitario A Coruña,15006 A Coruña-Spain, A Coruña, Galicia, Spain, ²Rheumatology Research Group, Vall d’Hebron Hospital Research Institute, Barcelona, Spain., Barcelona, Catalonia, Spain, ³UGC Reumatología, Instituto de Investigación Biomédica (IBIMA), Hospital Regional Universitario de Málaga, Spain., Málaga, Andalucia, Spain, ⁴Hospital Universitario Guadalajara, Guadalajara, Spain., Guadalajara, Castilla-La Mancha, Spain, ⁵Vall d’Hebron Hospital, Barcelona, Catalonia, Spain, ⁶Servicio de Reumatología. Instituto de Investigación Biomédica de A Coruña (INIBIC). Complexo Hospitalario Universitario de A Coruña (CHUAC), Sergas. Universidade da Coruña (UDC). As Xubias, 15006. A Coruña, España, A Coruña, Spain
Background/Purpose: Rheumatoid arthritis (RA) is a long-lasting inflammatory autoimmune disorder that ultimately leads to the destruction of joint architecture. The activity of this disease is…
Abstract Number: 1355 • 2019 ACR/ARP Annual Meeting
A Comparison of Clinical Improvement Following a Major Therapeutic Change Utilizing Updated Treatment Thresholds Defined by Three Different Disease Activity Measures
Grant Cannon¹, Wei Chen ¹, JIncheng Shen ², Neil Accortt ³, David Collier ⁴ and Brian Sauer ¹, ¹Salt Lake City VA Medical Center and Univeristy of Utah, Salt Lake City, UT, ²Univeristy of Utah, Salt Lake City, UT, ³Amgen, Thousand Oaks, CA, ⁴Amgen Inc., Thousand Oaks, CA
Background/Purpose: Despite ACR recommendations to initiate a major therapeutic change (MTC) in rheumatoid arthritis (RA) patients with moderate/severe disease activity, our recent work has shown…
Abstract Number: 2483 • 2019 ACR/ARP Annual Meeting
Comparison Between Composite Activity Indices to Assess Clinical Response to Biological Therapy in Patients with Psoriatic Arthritis
Diego Benavent¹, Chamaida Plasencia ², Victoria Navarro-Compán ³, Diana Peiteado ⁴, Laura Nuño ⁵, Irene Monjo ⁶, Elisa Fernández ⁷ and Alejandro Balsa ², ¹Hospital Universitario La Paz, Madrid, Spain, ²Immuno-Rheumatology Research Group, IdiPaz & Rheumatology Department. La Paz University Hospital, Madrid, Spain, ³University Hospital La Paz, IdiPaz, Madrid, Spain, ⁴Hospital Universitario La Paz, Madrid, ⁵Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, MADRID, Spain, ⁶FIBHULP-IdiPAZ-Hospital La Paz-Rheumatology, Madrid, Spain, ⁷Rheumatology Department, La Paz University Hospital, Madrid, Madrid, Spain
Background/Purpose: Assessment of the disease in psoriatic arthritis (PsA) remains a clinical challenge. Hence, there is no agreement on which index best correlates with the…
Abstract Number: 46 • 2019 ACR/ARP Annual Meeting
Key Inflammatory Biomarkers at Baseline Are Associated with Filgotinib Response at Week 12 in Rheumatoid Arthritis Patients with Inadequate Response or Intolerance to Biologic DMARDs
Peter Taylor¹, Emon Elboudwarej ², Bryan Downie ³, Rachael Hawtin ², Jinfeng Liu ² and Amer M. Mirza ², ¹University of Oxford, Oxford, United Kingdom, ²Gilead Sciences, Inc., Foster City, CA, ³Gilead Sciences, Inc., Foster Citty, CA
Background/Purpose: Filgotinib (FIL), an oral, selective, Janus Kinase 1 (JAK1) inhibitor was effective in Phase 3 studies of active RA in patients (pts) with inadequate…
Abstract Number: 1357 • 2019 ACR/ARP Annual Meeting
Leptin-adjustment of the Multi-biomarker Disease Activity (MBDA) Score Reduces the Influence of Adiposity
Joshua Baker¹, Jeffrey Curtis ², David Chernoff ³ and Michael George ⁴, ¹University of Pennsylvania, Philadelphia, PA, ²University of Alabama at Birmingham, Birmingham, AL, ³Myriad Genetics, Inc, Salt Lake City, UT, ⁴University of Pennsylvania, Philadelphia
Background/Purpose: Obesity and excess adiposity influence inflammatory markers and bias assessments of disease activity, most notably among women. A leptin-adjusted multi-biomarker disease activity (MBDA-LA) score…
Abstract Number: 2515 • 2019 ACR/ARP Annual Meeting
Disease Activity Influences Cardiovascular Risk Reclassification Based on Carotid Ultrasound in Patients with Psoriatic Artrhitis
Natalia Palmou-Fontana¹, DAVID MARTINEZ-LOPEZ ², ALFONSO CORRALES ³, Fernanda Genre ⁴, SUSANA ARMESTO ⁵, MARCOS GONZALEZ ⁶, PATRICIA VICENTE-GOMEZ ⁷, JAVIER GARCIA-FERNANDEZ ⁶, VIRGINIA PORTILLA- GONZALEZ ⁵, MONICA PEREZ-ANDRES ⁵, Mónica Calderón-Goercke ⁸, DIANA PRIETO- PENA ¹, Ricardo Blanco ⁹, JOSE LUIS HERNANDEZ ¹⁰, MIGUEL ANGEL GONZALEZ-GAY ¹¹ and Iván Ferraz-Amaro ¹², ¹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ²Hospital Universitario Marqués de Valdecilla, Santander, Cantabria, Spain, ³Universitary Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁴Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, IDIVAL, Santander, Spain, Santander, Spain, ⁵UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, Cantabria, Spain, ⁶UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, Cantabria, Spain, ⁷Hospital Universitario Marques de Valdecilla, Santander, Cantabria, Spain, ⁸Hospital Marqués de Valdecilla, Santander, Cantabria, Spain, ⁹Rheumatology, Hospital Universitario Marques de Valdecilla, Santander, Spain, ¹⁰UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, ¹¹UNIVERSITARY HOSPITAL MARQUES DE VALDECILLA, Santander, ¹²Rheumatology Division, Hospital Universitario de Canarias, Tenerife, Spain, Tenerife, Spain
Background/Purpose: Objectives. The addition of carotid ultrasound CU into composite cardiovascular risk (CVR) scores has been found useful in the identification of high CVR in…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].